Імунотерапія раку порожнини рота і ротоглотки
DOI:
https://doi.org/10.24061/2413-0737.XXIV.1.93.2020.32Ключові слова:
рак, порожнина рота, ротоглотка, імунотерапіяАнотація
Мета роботи – провести огляд наукових робіт, в яких висвітлювалися види, способи, методи імунотерапії хворих на рак порожнини рота і ротоглотки. Аналізувати результати досліджень у лікуванні раку порожнини рота і ротоглотки з використанням імунопрепаратів та можливості їх застосування.
Висновки. 1. Імуномодулюючі методи лікування, які долають імуносупресивні сигнали у хворих на рак порожнини рота і ротоглотки, є науково і терапевтично обґрунтованими. 2. Імунологічна терапія має потенціал для вирішення клінічних проблем у хворих на рак порожнини рота і ротоглотки шляхом поєднання із специфічними методами лікування. 3. Включення імунотерапевтичних препаратів до схеми комплексного лікування хворих на рак порожнини рота і ротоглотки значно покращує показники виживаності.
Посилання
Li Q, Prince ME, Moyer JS. Immunotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2015;51(4):299-304. doi: 10.1016/j.oraloncology.2014.12.005.
Bell RB, Leidner R, Feng Z, Crittenden MR, Gough MJ, Fox BA. Developing an Immunotherapy Strategy for the Effective Treatment of Oral, Head and Neck Squamous Cell Carcinoma. J Oral Maxillofac Surg. 2015;73(12):S107-15. doi: 10.1016/j.joms.2015.05.026.107-S15.
Siveen KS, Kuttan G. Role of macrophages in tumor progression. Immunol Lett. 2009;123(2):97-102. doi: 10.1016/j.imlet.2009.02.011.
Wang T, Niu G, Kottylewski M, Burdelya L, Shain K, Zhang S, et al. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med. 2004;10(1):48-54.
Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. Inhibiting Stat3 signalling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med. 2005;11(12):1314-21.
Agada FO, Alhamarneh O, Stafford ND, Greenman J. Immunotherapy in head and neck cancer: current practice and future possibilities. J Laryngol Otol. 2009;123(1):19-28. doi: 10.1017/S0022215108003356.
Raval RR, Sharabi AB, Walker AJ, Drake CG, Sharma P. Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer. J Immunother Cancer. 2014;2:14. doi: 10.1186/2051-1426-2-14. eCollection 2014.
Fishman MN, Thompson JA, Pennock GK, Gonzalez R, Diez LM, Daud AI, et al. Phase I trial of ALT-801, an interleukin-2/ T-cell receptor fusion protein targeting p53 (aa264–272)/HLAA*0201 complex, in patients with advanced malignancies. Clin Cancer Res. 2011;17(24):7765-75. DOI:10.1158/1078-0432. CCR-11-1817.
Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, et al. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210(4):474-84.
Rossig C, Brenner MK. Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 2004;10(1):5-18. DOI:10.1016/j.ymthe. 2004.04.014.
Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, et al. T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/gammacnull mice. Cancer Sci. 2012;103(1):17-25. doi: 10.1111/j.1349-7006.2011. 02111.x.
Whiteside TL, Letessier E, Hirabayashi H, Vitolo D, Bryant J, Barnes L, et al. Evidence for local and systemic activation of immune cells by peritumoral injectios of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck. Cancer Res. 1993;53(23):5654-62.
De Stefani A, Forni G, Ragona R, Cavallo G, Bussi M, Usai A, et al. Improved survival with perilymphatic interleukin 2 in patients with resectable squamous cell carcinoma of the oral cavity and oropharynx. Cancer. 2002;95(1):90-7.
Rapidis AD, Wolf GT. Immunotherapy of head and neck cancer:
current and future considerations. J Oncol. 2009;2009. Article ID 346345. DOI:10.1155/2009/346345.
van Herpen CM, Looman M, Zonneveld M, Scharenborg N, de Wilde PC, van de Locht L, et al. Intratumoral administration of recombinant human interleukin 12 in head and neck squamous cell carcinoma patients elicits a T-Helper 1 profile in the locoregional lymph nodes. Clin Cancer Res. 2004;10(8):2626-35.
Tugues S, Burkhard SH, Ohs I, Vrohlings M, Nussbaum K, Vom Berg J, et al. New insights into IL-12-mediated tumor suppression. Cell Death Differ. 2015;22(2):237-46. doi: 10.1038/cdd.2014.134.
Richtsmeier WJ, Koch WM, McGuire WP, Poole ME, Chang EH. Phase I-II study of advanced head and neck squamous cell carcinoma patients treated with recombinant human interferon gamma. Arch Otolaryngol Head Neck Surg. 1990;116(11):1271-7.
Bazarbashi S, Rahal M, Raja MA, El Weshi A, Pai C, Ezzat A, et al. A pilot trial of combination cisplatin, 5-fluorouracil and interferon-alpha in the treatment of advanced esophageal carcinoma. Chemotherapy. 2002;48(4):211-16.
Seixas-Silva JA, Richards T, Khuri FR, Wieand HS, Kim MD, Murphy B, ed al. Phase 2 bioadjuvant study of interferon alfa-2a, isotretinoin, and vitamin E in locally advanced squamous cell carcinoma of the head and neck: long-term follow-up. Arch Otolaryngol Head Neck Surg. 2005;131(4):304-7.
Urba SG, Forastiere AA, Wolf GT, Amrein PC. Intensive recombinant
interleukin-2 and alpha-interferon therapy in patients with advanced head and neck squamous carcinoma. Cancer. 1993;71(7):2326-31.
Mahjoubi R, Bachouchi M, Munck JN, Busson P, Gasmi J, Azli N, et al. Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx. Head Neck. 1993;15(2):115-8.
Czystowska M, Han J, Szczepanski MJ, Szajnik M, Quadrini K, Brandwein H, et al. IRX-2, a novel immunotherapeutic, protects human T cells from tumor-induced cell death. Cell Death Differ. 2009;16(5):708-18. doi: 10.1038/cdd.2008.197.
Wolf GT, Fee WE, Dolan RW, Moyer JS, Kaplan MJ, Spring PM, et al. Novel neoadjuvant immunotherapy regimen safety and survival in head and neck squamous cell cancer. Head Neck. 2011;33(12):1666-74. doi: 10.1002/hed.21660.
Wolf GT, Moyer JS, Kaplan MJ, Newman JG, Egan JE, Berinstein NL, et al. IRX-2 natural cytokine biologic for immunotherapy in patients with head and neck cancers. Onco Targets Ther. 2018;11:3731-746. doi: 10.2147/OTT.S165411.
Schilling B, Halstead ES, Schuler P, Harasymczuk M, Egan JE, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances and protects NK-cell functions in cancer patients. Cancer Immunol Immunother. 2012;61(9):1395-405.
Schilling B, Harasymczuk M, Schuler P, Egan J, Ferrone S, Whiteside TL. IRX-2, a novel immunotherapeutic, enhances functions of human dendritic cells. PLoS ONE. 2013;8(2):e47234.
Yewdell JW. DRiPs solidify: рrogress in understanding endogenous MHC class I antigen processing. Trends Immunol. 2011;32(11):548-58. doi: 10.1016/j.it.2011.08.001.
Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg. 2011;45:341-60.
Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med. 2009;361(19):1838-47. doi: 10.1056/NEJMoa0810097.
Schlom J, Hodge JW, Palena C, Tsang KY, Jochems C, Greiner JW, et al. Therapeutic cancer vaccines. Adv Cancer Res. 2014;121:67-124. doi: 10.1016/B978-0-12-800249-0.00002-0.
Bauman JE, Gooding WE, Clump DA, Kim S, Karlovits BJ, Heron DE. Phase I trial of cetuximab, intensity modulated radiotherapy (IMRT), and the anti-CTLA-4 monoclonal antibody (mAb) ipilimumab in previously untreated, locally advanced head and neck squamous cell carcinoma (PULA HNSCC). J Clin Oncol. 2014;32. DOI: 10.1200/jco.2014.32.15_suppl.tps6104.
D’Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944-56.
Voskens CJ, Sewell D, Hertzano R, DeSanto J, Rollins S, Lee M, et al. Induction of MAGE-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma. Head Neck. 2012;34(12):1734-46. doi: 10.1002/hed.22004.
Pai S, Smith D, Peng S. Therapeutic HPV vaccine increases sensitivity of poorly immunogenic tumor to anti-PD-1 monotherapy. Presented at: fifth international conference on innovative approaches in head and neck oncology. Nice; 2015.
Li W, Joshi MD, Singhania S, Ramsey KH, Murthy AK. Peptide Vaccine: Progress and Challenges. Vaccines (Basel). 2014;2(3):515-36. doi: 10.3390/vaccines2030515.
Yoshitake Y, Fukuma D, Yuno A, Hirayama M, Nakayama H, Tanaka T, et al. Phase II clinical trial of multiple peptide vaccination for advanced head and neck cancer patients revealed induction of immune responses and improved OS. Clin Cancer Res. 2015;21(2):312-21. doi: 10.1158/1078-0432.CCR-14-0202.
Andrade P, Deleo A, Visus C, Butterfield L, Argiris A, Ferris RL. Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:15.
Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, et al. Phase I dendritic cell p53 peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20(9):2433-44. doi: 10.1158/1078-0432.CCR-13-2617.
Jiang P, Zhang Y, Archibald SJ, Wang H. Adoptive cell transfer after chemotherapy enhances survival in patients with resectable HNSCC. Int Immunopharmacol. 2015;28(1):208-14. doi: 10.1016/j.intimp.2015.05.042.
Croker AK, Allan AL. Cancer stem cells: implications for the progression and treatment of metastatic disease. J Cell Mol Med. 2008;12(2):374-90. DOI.org/10.1111/j.1582-4934.2007.00211.x.
Mеry B, Guy J-B, Espenel S, Wozny A-S, Simonet S, Vallard A, et al. Targeting head and neck tumoral stem cells: From biological aspects to therapeutic perspectives. World J Stem Cells. 2016;8(1):13-21. doi: 10.4252/wjsc.v8.i1.13.
Hirohashi Y, Torigoe T, Tsukahara T, Kanaseki T, Kochin V, Sato N. Immune responses to human cancer stem-like cells/cancer-initiating cells. Cancer Sci. 2016;107(1):12-7. doi: 10.1111/cas.12830.
Prince ME, Sivanandan R, Kaczorowski A, Wolf GT, Kaplan MJ, Dalerba P, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA. 2007;104(3):973-8.
Clay MR, Tabor M, Owen JH, Carey TE, Bradford CR, Wolf GT, et al. Single-marker identification of head and neck squamous cell carcinoma cancer stem cells with aldehyde dehydrogenase. Head Neck. 2010;32(9):1195-201. doi: 10.1002/hed.21315.
Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci USA. 1999;96(15):8639-44.
Visus C, Wang Y, Lozano-Leon A, Ferris RL, Silver S, Szczepanski MJ, et al. Targeting ALDH (bright) human carcinoma-initiating cells with ALDH1A1-specific CD8+ T cells. Clin Cancer Res. 2011;17(19):6174-84. doi: 10.1158/1078-0432.CCR-11-1111.
Visus C, Ito D, Amoscato A, Maciejewska-Franczak M, Abdelsalem A, Dhir R, et al. Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. Cancer Res. 2007;67(21):10538-45.
Huang J, Li C, Wang Y, Lv H, Guo Y, Dai H, et al. Cytokine-induced killer (CIK) cells bound with anti-CD3/anti-CD133 bispecific antibodies target CD133(high) cancer stem cells in vitro and in vivo. Clin Immunol. 2013;149(1):156-68. doi: 10.1016/j.clim.2013.07.006.
Ning N, Pan Q, Zheng F, Teitz-Tennenbaum S, Egenti M, Yet J, et al. Cancer stem cell vaccination confers significant antitumor immunity. Cancer Res. 2012;72(7):1853-64. doi: 10.1158/0008-5472.CAN-11-1400.
Burtness B, Bauman JE, Galloway T. Novel targets in HPV-negative head and neck cancer: overcoming resistance to EGFR inhibition. Lancet Oncol. 2013;14(8):e302-9. doi: 10.1016/s1470-2045(13)70085-8.
Choong NW, Kozloff M, Taber D, Hu HS, Wade J 3rd, Ivy P, et al. Phase II study of sunitinib malate in head and neck squamous cell carcinoma. Invest New Drugs. 2010;28(5):677-83. doi: 10.1007/s10637-009-9296-7.
Fountzilas G, Fragkoulidi A, Kalogera-Fountzila A, Nikolaidou M, Bobos M, Calderaro J, et al. A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer. Cancer Chemother Pharmacol. 2010;65(4):649-60. doi:10.1007/s00280-009-1070-1.
Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N, Rommel D, et al. Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01. J Clin Oncol. 2010;28(1):21-8. doi: 10.1200/JCO.2009.23.8584.
Garrity T, Pandit R, Wright MA, Benefield J, Keni S, Young MR. Increased presence of CD34? cells in the peripheral blood of head and neck cancer patients and their differentiation into dendritic cells. Int J Cancer. 1997;73(5):663-9.
Young MR, Wright MA, Vellody K, Lathers DM. Skewed differentiation of bone marrow CD34 cells of tumor bearers from dendritic toward monocytic cells, and the redirection of differentiation toward dendritic cells by 1alpha,25-dihydroxyvitamin D3. Int J Immunopharmacol. 1999;21(10):675-88.
Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-Dihydroxyvitamin D3 (Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007;6(4):1433-9. doi: 10.1158/1535-7163.MCT-06-0677.
Walsh JE, Clark AM, Day TA, Gillespie MB, Young MR. Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma. Hum Immunol. 2010;71(7):659-65. doi: 10.1016/j.humimm.2010.04.008.
Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res. 2007;13(2):721s–6s. DOI: 10.1158/1078-0432.CCR-06-2197.
Kao J, Genden EM, Chen CT, Rivera M, Tong CC, Misiukiewicz K, et al. Phase 1 trial of concurrent erlotinib, celecoxib, and reirradiation for recurrent head and neck cancer. Cancer. 2011;117(14):3173-81. doi: 10.1002/cncr.25786.
Wirth LJ, Haddad RI, Lindeman NI, Zhao X, Lee JC, Joshi VA, et al. Phase I study of gefitinib plus celecoxib in recurrent or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol. 2005;23(28):6976-81. doi: 10.1200/JCO.2005.02.4182.
Dajani EZ, Islam K. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man. J Physiol Pharmacol. 2008;59(2):117-33.
Serafini P, Meckel K, Kelso M, Noonan K, Califano J, Koch W, et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function. J Exp Med. 2006;203(12):2691-702.
Serafini P, Mgebroff S, Noonan K, Borrello I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008;68(13):5439-49. doi: 10.1158/0008-5472.CAN-07-6621.
Ghiringhelli F, Menard C, Puig PE, Ladoire S, Roux S, Martin F, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56(5):641-8. doi: 10.1007/s00262-006-0225-8.
Recchia F, Lalli A, Lombardo M, De Filippis S, Saggio G, Fabbri F, et al. Ifosfamide, cisplatin, and 13-Cis retinoic acid for patients with advanced or recurrent squamous cell carcinoma of the head and neck: a phase I–II study. Cancer. 2001;92(4):814-21.
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2020 H. A. Hirna, I. D. Kostyshyn, M. M. Rozhko, R. A. Levandovskyi
Ця робота ліцензованаІз Зазначенням Авторства 3.0 Міжнародна.
Автори залишають за собою право на авторство своєї роботи та передають журналу право першої публікації цієї роботи на умовах ліцензії Creative Commons Attribution License, котра дозволяє іншим особам вільно розповсюджувати опубліковану роботу з обов'язковим посиланням на авторів оригінальної роботи та першу публікацію роботи у цьому журналі.
Автори мають право укладати самостійні додаткові угоди щодо неексклюзивного розповсюдження роботи у тому вигляді, в якому вона була опублікована цим журналом (наприклад, розміщувати роботу в електронному сховищі установи або публікувати у складі монографії), за умови збереження посилання на першу публікацію роботи у цьому журналі.
Політика журналу дозволяє і заохочує розміщення авторами в мережі Інтернет (наприклад, у сховищах установ або на особистих веб-сайтах) рукопису роботи, як до подання цього рукопису до редакції, так і під час його редакційного опрацювання, оскільки це сприяє виникненню продуктивної наукової дискусії та позитивно позначається на оперативності та динаміці цитування опублікованої роботи (див. The Effect of Open Access).
